Evidence map›Paper›PMID 31739477›Full record

ArticleCells2019

Development of a Stromal Microenvironment Experimental Model Containing Proto-Myofibroblast Like Cells and Analysis of Its Crosstalk with Melanoma Cells: A New Tool to Potentiate and Stabilize Tumor Suppressor Phenotype of Dermal Myofibroblasts.

Angelica Avagliano, Maria Rosaria Ruocco, Rosarita Nasso, Federica Aliotta, Gennaro Sanità, Antonino Iaccarino, Claudio Bellevicine, Gaetano Calì, Giuseppe Fiume, Stefania Masone and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Angelica AvaglianoDepartment of Public Health, University of Naples Federico II, 80131 Naples, Italy.
Maria Rosaria RuoccoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.
Rosarita NassoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.
Federica AliottaDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.
Gennaro SanitàDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.
Antonino IaccarinoDepartment of Public Health, University of Naples Federico II, 80131 Naples, Italy.
Claudio BellevicineDepartment of Public Health, University of Naples Federico II, 80131 Naples, Italy.
Gaetano CalìIEOS Istituto di Endocrinologia e Oncologia Sperimentale 'G. Salvatore', National Council of Research, 80131 Naples, Italy.ORCID 0000-0003-2901-2374
Giuseppe FiumeDepartment of Experimental and Clinical Medicine, University of Catanzaro 'Magna Graecia', Viale Europa, 88100 Catanzaro, Italy.ORCID 0000-0002-5414-6190
Stefania MasoneDepartment of Clinical Medicine and Surgery, University of Naples Federico II, 80133 Naples, Italy.
Mariorosario MasulloDepartment of Movement Sciences and Wellness, University of Naples 'Parthenope', 80133 Naples, Italy.ORCID 0000-0003-4485-7383
Stefania MontagnaniDepartment of Public Health, University of Naples Federico II, 80131 Naples, Italy.
Alessandro ArcucciDepartment of Public Health, University of Naples Federico II, 80131 Naples, Italy.
University of Naples Federico II · ITParthenope University of Naples · ITInstitute for Experimental Endocrinology and Oncology · ITMagna Graecia University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma is one of the most aggressive solid tumors and includes a stromal microenvironment that regulates cancer growth and progression. The components of stromal microenvironment such as fibroblasts, fibroblast aggregates and cancer-associated fibroblasts (CAFs) can differently influence the melanoma growth during its distinct stages. In this work, we have developed and studied a stromal microenvironment model, represented by fibroblasts, proto-myofibroblasts, myofibroblasts and aggregates of inactivated myofibroblasts, such as spheroids. In particular, we have generated proto-myofibroblasts from primary cutaneous myofibroblasts. The phenotype of proto-myofibroblasts is characterized by a dramatic reduction of α-smooth muscle actin (α-SMA) and cyclooxygenase-2 (COX-2) protein levels, as well as an enhancement of cell viability and migratory capability compared with myofibroblasts. Furthermore, proto-myofibroblasts display the mesenchymal marker vimentin and less developed stress fibers, with respect to myofibroblasts. The analysis of crosstalk between the stromal microenvironment and A375 or A2058 melanoma cells has shown that the conditioned medium of proto-myofibroblasts is cytotoxic, mainly for A2058 cells, and dramatically reduces the migratory capability of both cell lines compared with the melanoma-control conditioned medium. An array analysis of proto-myofibroblast and melanoma cell-conditioned media suggests that lower levels of some cytokines and growth factors in the conditioned medium of proto-myofibroblasts could be associated with their anti-tumor activity. Conversely, the conditioned media of melanoma cells do not influence the cell viability, outgrowth, and migration of proto-myofibroblasts from spheroids. Interestingly, the conditioned medium of proto-myofibroblasts does not alter the cell viability of both BJ-5ta fibroblast cells and myofibroblasts. Hence, proto-myofibroblasts could be useful in the study of new therapeutic strategies targeting melanoma.

Indexed as

ActinsAdultCell CommunicationCell Line, TumorCell MovementCells, CulturedCell SurvivalCellular MicroenvironmentCulture Media, ConditionedCyclooxygenase 2FemaleHumansMelanomaMiddle AgedMyofibroblastsPhenotypeACTA2 protein, humanActinsCulture Media, ConditionedCyclooxygenase 2PTGS2 protein, humanVimentinVIM protein, humanconditioned mediummelanomaproto-myofibroblastsstromal microenvironment

Identifiers

PMID31739477
PMCPMC6912587
OpenAlexW2983565491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.